226 related articles for article (PubMed ID: 25961724)
21. The potential of osteopontin as a therapeutic target for human colorectal cancer.
Likui W; Hong W; Shuwen Z; Yuangang Y; Yan W
J Gastrointest Surg; 2011 Apr; 15(4):652-9. PubMed ID: 21318445
[TBL] [Abstract][Full Text] [Related]
22. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells.
Huang J; Pan C; Hu H; Zheng S; Ding L
PLoS One; 2012; 7(10):e47901. PubMed ID: 23112867
[TBL] [Abstract][Full Text] [Related]
23. Elevated serum concentration of monocyte chemotactic protein 4 (MCP-4) as a novel non-invasive prognostic and predictive biomarker for detection of metastasis in colorectal cancer.
Okugawa Y; Toiyama Y; Mohri Y; Tanaka K; Kawamura M; Hiro J; Araki T; Inoue Y; Miki C; Kusunoki M
J Surg Oncol; 2016 Sep; 114(4):483-9. PubMed ID: 27349356
[TBL] [Abstract][Full Text] [Related]
24. Plasma osteopontin as a biomarker of prostate cancer aggression: relationship to risk category and treatment response.
Thoms JW; Dal Pra A; Anborgh PH; Christensen E; Fleshner N; Menard C; Chadwick K; Milosevic M; Catton C; Pintilie M; Chambers AF; Bristow RG
Br J Cancer; 2012 Aug; 107(5):840-6. PubMed ID: 22871886
[TBL] [Abstract][Full Text] [Related]
25. Serum haptoglobin as a novel molecular biomarker predicting colorectal cancer hepatic metastasis.
Sun L; Hu S; Yu L; Guo C; Sun L; Yang Z; Qi J; Ran Y
Int J Cancer; 2016 Jun; 138(11):2724-31. PubMed ID: 26756179
[TBL] [Abstract][Full Text] [Related]
26. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer.
Plumer A; Duan H; Subramaniam S; Lucas FL; Miesfeldt S; Ng AK; Liaw L
BMC Cancer; 2008 Jan; 8():38. PubMed ID: 18237408
[TBL] [Abstract][Full Text] [Related]
27. The utility of serum osteopontin levels for predicting postoperative complications after colorectal cancer surgery.
Sekiguchi K; Matsuda A; Yamada M; Matsumoto S; Sakurazawa N; Kawano Y; Yamada T; Miyashita M; Yoshida H
Int J Clin Oncol; 2022 Nov; 27(11):1706-1716. PubMed ID: 35951171
[TBL] [Abstract][Full Text] [Related]
28. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels.
Rai AJ; Flores RM; Mathew A; Gonzalez-Espinoza R; Bott M; Ladanyi M; Rusch V; Fleisher M
Clin Chem Lab Med; 2010 Feb; 48(2):271-8. PubMed ID: 20131968
[TBL] [Abstract][Full Text] [Related]
29. Osteopontin level and promoter polymorphism in patients with metastatic breast cancer.
Elbaiomy MA; Akl T; Elhelaly R; El-Beshbishi W; El Ghonemy MS; Elzehery R
Curr Oncol; 2020 Oct; 27(5):e444-e450. PubMed ID: 33173383
[TBL] [Abstract][Full Text] [Related]
30. Circulating miR-103 and miR-720 as novel serum biomarkers for patients with colorectal cancer.
Nonaka R; Miyake Y; Hata T; Kagawa Y; Kato T; Osawa H; Nishimura J; Ikenaga M; Murata K; Uemura M; Okuzaki D; Takemasa I; Mizushima T; Yamamoto H; Doki Y; Mori M
Int J Oncol; 2015 Sep; 47(3):1097-102. PubMed ID: 26134152
[TBL] [Abstract][Full Text] [Related]
31. Identification of secretory gelsolin as a plasma biomarker associated with distant organ metastasis of colorectal cancer.
Tsai MH; Wu CC; Peng PH; Liang Y; Hsiao YC; Chien KY; Chen JT; Lin SJ; Tang RP; Hsieh LL; Yu JS
J Mol Med (Berl); 2012 Feb; 90(2):187-200. PubMed ID: 21997591
[TBL] [Abstract][Full Text] [Related]
32. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma.
Hollevoet K; Nackaerts K; Gosselin R; De Wever W; Bosquée L; De Vuyst P; Germonpré P; Kellen E; Legrand C; Kishi Y; Delanghe JR; van Meerbeeck JP
J Thorac Oncol; 2011 Nov; 6(11):1930-7. PubMed ID: 21841505
[TBL] [Abstract][Full Text] [Related]
33. Significant peri-operative reduction in plasma osteopontin levels after coronary artery by-pass grafting.
Sbarouni E; Georgiadou P; Mihas C; Chaidaroglou A; Degiannis D; Voudris V
Clin Biochem; 2012 Nov; 45(16-17):1513-5. PubMed ID: 22580396
[TBL] [Abstract][Full Text] [Related]
34. New dual monoclonal ELISA for measuring plasma osteopontin as a biomarker associated with survival in prostate cancer: clinical validation and comparison of multiple ELISAs.
Anborgh PH; Wilson SM; Tuck AB; Winquist E; Schmidt N; Hart R; Kon S; Maeda M; Uede T; Stitt LW; Chambers AF
Clin Chem; 2009 May; 55(5):895-903. PubMed ID: 19325010
[TBL] [Abstract][Full Text] [Related]
35. Presence of Twist1-positive neoplastic cells in the stroma of chromosome-unstable colorectal tumors.
Celesti G; Di Caro G; Bianchi P; Grizzi F; Basso G; Marchesi F; Doni A; Marra G; Roncalli M; Mantovani A; Malesci A; Laghi L
Gastroenterology; 2013 Sep; 145(3):647-57.e15. PubMed ID: 23684708
[TBL] [Abstract][Full Text] [Related]
36. Reduction of elevated plasma osteopontin levels with resection of non-small-cell lung cancer.
Blasberg JD; Pass HI; Goparaju CM; Flores RM; Lee S; Donington JS
J Clin Oncol; 2010 Feb; 28(6):936-41. PubMed ID: 20085934
[TBL] [Abstract][Full Text] [Related]
37. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial.
Bramwell VH; Tuck AB; Chapman JA; Anborgh PH; Postenka CO; Al-Katib W; Shepherd LE; Han L; Wilson CF; Pritchard KI; Pollak MN; Chambers AF
Breast Cancer Res; 2014 Jan; 16(1):R8. PubMed ID: 24451146
[TBL] [Abstract][Full Text] [Related]
38. Plasma levels of angiopoietin-like protein 4 (ANGPTL4) are significantly lower preoperatively in colorectal cancer patients than in cancer-free patients and are further decreased during the first month after minimally invasive colorectal resection.
Shantha Kumara HM; Kirchoff D; Herath SA; Jang JH; Yan X; Grieco M; Cekic V; Whelan RL
Surg Endosc; 2012 Oct; 26(10):2751-7. PubMed ID: 22549372
[TBL] [Abstract][Full Text] [Related]
39. Elevated content of osteopontin in plasma and tumor tissues of patients with laryngeal and hypopharyngeal carcinoma associated with metastasis and prognosis.
Li Y; Li L; Wang JT; Kan X; Lu JG
Med Oncol; 2012 Sep; 29(3):1429-34. PubMed ID: 21706367
[TBL] [Abstract][Full Text] [Related]
40. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study.
Park MG; Oh MM; Yoon JH; Park JY; Park HS; Moon DG; Yoon DK
Kaohsiung J Med Sci; 2012 Oct; 28(10):526-30. PubMed ID: 23089317
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
